UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000056566
Receipt number R000064645
Scientific Title A preliminary study to confirm the effects of two test foods on alcohol metabolism
Date of disclosure of the study information 2025/01/11
Last modified on 2024/12/25 16:45:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A preliminary study to confirm the effects of two test foods on alcohol metabolism

Acronym

A preliminary study to confirm the effects of two test foods on alcohol metabolism

Scientific Title

A preliminary study to confirm the effects of two test foods on alcohol metabolism

Scientific Title:Acronym

A preliminary study to confirm the effects of two test foods on alcohol metabolism

Region

Japan


Condition

Condition

Healty volunteers

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

A pilot study to confirm the effects of ingesting two types of test foods for two weeks on alcohol metabolism

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Blood alcohol concentration

Key secondary outcomes

POMS2


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Oral intake of test food A for 2 weeks

Interventions/Control_2

Oral intake of test food B for 2 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >=

Gender

Male

Key inclusion criteria

1)Adult males aged 20 to 70
2) Those who can drink 12.5% shochu
3) Those weighing between 50.0 kg and 90.0 kg
4) Those who are deemed by the principal investigator or sub-investigator to have no problem participating in this study
5) Those who can give written informed consent to participate in the study

Key exclusion criteria

1) Those who have been taking medication regularly within 3 months prior to the start of the study (Excluding temporary painkillers, cold medicines, etc.)
2) Those with serious illnesses (diabetes, heart disease, liver disease, kidney disease, cancer, etc.) or mental illnesses
3) Those with a history of serious illness (diabetes, heart disease, liver disease, kidney disease, cancer, etc.) or digestive system disease
4) Those who have regularly taken specific health foods, functional foods, health foods (including supplements), etc., that may affect the study, at least three times a week within three months prior to the start of the study.
5) Those who cannot stop taking foods for specified health uses, foods with functional claims, health foods (including supplements), etc. that may affect the study during the study period.
6) Those who cannot drink alcohol
7) Those who regularly use medicines, health foods, foods for specified health uses, or foods with functional claims that may affect liver function
8) Night shift and day/night shift workers
9) Those who regularly drink large amounts of alcohol 3 or more days a week (40g or more of pure alcohol per day)
10) Those with extremely irregular eating habits or those with irregular lifestyles such as working night shifts
11) Those with drug or food allergies
12) Those who are currently participating in a clinical trial of another drug or health food, have completed the trial within 4 weeks, or are scheduled to participate in another clinical trial while participating in this trial.
13) Those who are deemed ineligible to participate in this study by the investigator

Target sample size

14


Research contact person

Name of lead principal investigator

1st name Tadashi
Middle name
Last name Watanabe

Organization

Watanabe Hospital

Division name

chairperson

Zip code

144-0043

Address

1-5-16, Haneda, Ota-ku, Tokyo, Japan

TEL

03-3741-0223

Email

wnb.cto@gmail.com


Public contact

Name of contact person

1st name Tatsuo
Middle name
Last name Uetake

Organization

CXwellness, Inc.

Division name

Representative Directo

Zip code

173-0004

Address

2-63-9-401 Itabashi, Itabashi-ku, Tokyo JAPAN

TEL

03-6915-5507

Homepage URL


Email

uetake@cx-wellness.com


Sponsor or person

Institute

MITSUBISHI GAS CHEMICAL COMPANY, INC.

Institute

Department

Personal name



Funding Source

Organization

MITSUBISHI GAS CHEMICAL COMPANY, INC.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Review Committee of Watanabe Hospital

Address

1-5-16, Haneda, Ota-ku, Tokyo, JAPAN

Tel

03-3741-0223

Email

wnb@cto-net.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 01 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2024 Year 12 Month 11 Day

Date of IRB

2024 Year 12 Month 25 Day

Anticipated trial start date

2025 Year 01 Month 13 Day

Last follow-up date

2025 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 12 Month 25 Day

Last modified on

2024 Year 12 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064645